NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Health / Surgery
Agency / Source: NEC Corporation

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status - Financing Will Expedite R&D, Clinical Expansion, and International Availability of BostonGene Tumor Portrait™ Tests - BostonGene.com / NEC.com
BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status

 

NewswireTODAY - /newswire/ - Waltham, MA, United States, 2022/04/06 - Financing Will Expedite R&D, Clinical Expansion, and International Availability of BostonGene Tumor Portrait™ Tests - BostonGene.com / NEC.com. NEC; TSE: 6701

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BostonGene today announced the completion of $150 million in Series B funding. NEC Corporation led the financing with participation from Impact Investment Capital and Japan Industrial Partners. The capital will be used to scale BostonGene's growth, including continued innovation, clinical and research partnerships, and international expansion. Further, leveraging NEC's robust infrastructure, BostonGene and NEC intend to form a joint venture to bring lifesaving solutions to patients in Japan and other Asian countries.

“Many academic and community oncologists across the United States have already adopted BostonGene's Molecular Portrait Test to improve their patients' quality of care," said Takayuki Morita, President and CEO at NEC Corporation. “NEC recently launched a healthcare and life science business unit that utilizes AI and other digital technologies as a key initiative within our 2025 Mid-term Management Plan. We are thrilled to expand on our strategic partnership with BostonGene to advance how physicians treat their patients and dramatically improve clinical outcomes in the U.S., Japan, and the rest of the world."

“BostonGene has a unique opportunity to build a very large economic value that creates an even larger social impact. That combination is extremely rare, and I am excited and humbled by it," said Andrew Feinberg, President, and CEO at BostonGene. “This capital positions us well to execute on our vision to enable personalized treatment of cancer patients based on integrated molecular profiles of the tumor, tumor microenvironment, and host immunity."

BostonGene's innovative computational platform performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient's immune system, and the effectiveness of all available approved and investigational treatments. The BostonGene Tumor Portrait™ Tests, a sophisticated analysis of the tumor and tumor microenvironment (TME), reveals critical drivers of each tumor, including immune microenvironment properties, actionable mutations, and biomarkers of response to diverse therapies, and recommended therapies. BostonGene's integrated model of tumor genetics, transcriptomics, microenvironment, and tumor composition provides a 360° overview of a patient tumor to give physicians invaluable insights into potential treatment options.

About BostonGene Corporation

BostonGene’s mission (bostongene.com) is to power healthcare’s transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor Portrait™ Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor Portrait™ Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient.

About Impact Investment Capital

Impact Investment Capital invests in opportunities with the intention to generate a measurable, beneficial social or environmental impact alongside a financial return.

About Japan Industrial Partners, Inc.

Japan Industrial Partners (JIP) is a private equity firm based in Tokyo, Japan. JIP aims to provide funds and solutions to businesses with significant growth opportunities.

About NEC Corporation

NEC Corporation (nec.com) has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential.

NEC is a registered trademark of NEC Corporation. All Rights Reserved. Other product or service marks mentioned herein are the trademarks of their respective owners. ©2022 NEC Corporation.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: NEC Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!


BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BostonGene Tumor Portrait | NEC Corporation
Contact: Press Office - NEC.com 
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NEC Corporation securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NEC Corporation / Company Profile


Read Health / Surgery Most Recent Related Newswires:

GenieMD Awarded Frost & Sullivan’s 2024 Company of the Year Award for Pioneering Virtual Chronic Disease Management Solutions
Health Recovery Solutions (HRS) Applauded by Frost & Sullivan for Transforming Remote Care Delivery with its Clinically Enabled, Patient-centric RPM
Greenway Health Earns Frost & Sullivan’s 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Prod
Verista Awarded by Frost & Sullivan for Providing Next-Generation Compliance and Quality Management Solutions in the Life Sciences Industry
TeraRecon Applauded by Frost & Sullivan for Solving Time-related Challenges in Neurological Care and its Market-leading Position
Nagasaki University and NEC OncoImmunity Collaborate to Design Universal Vaccines Targeting Tropical Infectious Diseases
Subang Jaya Medical Centre Awarded Frost & Sullivan’s Company of the Year Award for the Third Consecutive Year
Sunway Medical Centre Velocity Awarded by Frost & Sullivan for Leading the Malaysian Hospital Industry with Holistic Medical Care
George Clinical Applauded by Frost & Sullivan for its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific Region
AvantGuard Applauded by Frost & Sullivan for Extending the Life of Chlorine-based Disinfectants for Sustained Efficacy with its Residual Antimicrobial
Infor and HARMAN Announce Strategic Partnership on Healthcare Delivery
Digital Transformation Across Life Sciences Industry Boosts Instrumentation Market According to Frost & Sullivan
Organizational-level, Unified and Vendor-neutral Enterprise Imaging and Informatics Drive Effective Digital Transformation
Rely+On Virkon from LANXESS Found to be Effective in Airborne Room Disinfection
Verana Health Receives New Product Innovation Award from Frost & Sullivan for its VeraQ Population Health Data Engine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NexGen Unlimited, LLC





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)